DMAPT

Research use only, not for human use.

DMAPT is a water-soluble analogue of Parthenolide (PTL).

DMAPT is a water-soluble analogue of Parthenolide (PTL). It is an orally active NF-κB inhibitor with an LD50 of 1.7 μM on primary acute myeloid leukemia cells.(In Vitro):DMAPT treatment reduced the constitutive NF-κB binding activity and inhibited the proliferation and viability of PC-3 and DU145 cells. Treatment of PC-3 and DU145 cells with 5 and 4 μM DMAPT, respectively, increased the population doubling time of PC-3 prostate cancer cells from 23.0±5.0 h to 42.0±3.0 h, while the population doubling time of DU145 cells increased from 20.4±2.2 h By 72.5±24.8 hours.(In Vivo):DMAPT (100 mg/kg, oral gavage daily for 7 days) treatment can increase the sensitivity of PC-3 tumor xenografts to X-rays. DMAPT (100 mg/kg, 42 to 300 days from birth, oral gavage three times a week) treatment can slow the normal tumor development of TRAMP mice and prolong the reachable prostate tumor time by 20%. DMAPT further reduced the lung tissue transfer area of TRAMP mice to below the water vehicle treatment group (0.10%±0.15 SD, 92% reduction, p = 0.0028).

——

——

Dimethylamino Parthenolide

Apoptosis

NF-κB

PI3K

——

——

870677-05-7

293.407

C17H27NO3

>98% (HPLC)

——

[H][C@@]12CC\C(C)=C/CC[C@@]3(C)O[C@@H]3[C@@]1([H])OC(=O)[C@@H]2CN(C)C

——

(-20℃)

With Ice Pack

≥ 2 years